Citadel Advisors’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Citadel Advisors’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-44,098	Closed	-$179K	–	15801
2023 Q4	$179K	Buy	+44,098	New	+$135K	﹤0.01%	10111
2023 Q3	–	Sell	-604,550	Closed	-$5.64M	–	15403
2023 Q2	$5.64M	Buy	604,550 +120,164	+25%	+$1.18M	﹤0.01%	3462
2023 Q1	$4.3M	Buy	+484,386	New	+$4.75M	﹤0.01%	4055

Citadel Advisors's THRX Position: Q1 2024 in Review

Citadel Advisors sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 44,098 shares — an estimated $179K sold.

Citadel Advisors first reported a position in THRX in Q1 2023 and held it in 3 quarters. The position peaked at $5.64M in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

Citadel Advisors reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 44,098 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $179K.
Citadel Advisors first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 3 quarters.
Citadel Advisors's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $5.64M in Q2 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.